Are GLP-1 and GIP Therapies Safe? Understanding the Risks and Side Effects

At
Battersea Hospital
we Understand the Side Effects of GLP‑1 and GIP Therapies

Doctor-led GLP-1 and GIP weight management consultation at Battersea Hospital

GLP‑1 (glucagon-like peptide‑1) and dual GLP‑1/GIP therapies such as semaglutide (Ozempic) and tirzepatide (Mounjaro) have transformed modern weight management. Their ability to regulate appetite, improve metabolic health, and drive significant
weight loss has made them increasingly popular in both NHS and private settings. However, as with any medical treatment, it is essential to understand the
potential side effects—and to approach therapy under proper clinical supervision.

Common Side Effects: Gastrointestinal Symptoms

The most frequently reported side effects of GLP‑1 and GIP medications are
gastrointestinal (GI) in nature. These include:



  • Nausea
  • Vomiting
  • Diarrhoea
  • Constipation
  • Reduced appetite

Clinical studies consistently show that these symptoms affect a significant proportion of patients. Evidence suggests that
40-50% of individuals experience GI symptoms, particularly during the early stages of treatment or dose escalation, although both Ozempic and Mounjaro have roughly the same amount of symptoms. These effects are usually mild to moderate and tend to improve over time as the body adapts.

This is why
doctor-led programmes carefully
titrate dosing over time, allowing the body to adjust and minimising discomfort. Without proper supervision, rapid dose increases can significantly worsen tolerability.

Less Common but Important Risks

Clinician reviewing patient health risks before GLP-1 or GIP therapy

While most side effects are manageable, there are
less common but clinically significant risks to be aware of:



  • Gallbladder disease (e.g. gallstones)
  • Delayed gastric emptying (gastroparesis)
  • Bowel obstruction (rare)
  • Pancreatitis (rare but serious)

These events are well known but thankfully
rare.

Importantly, broader reviews suggest that while early trials raised concerns about pancreatitis risk,
more recent large analyses do not confirm a clear class-wide increase in risk, highlighting the importance of individual assessment and monitoring. 

Emerging Considerations

As these medications become more widely used, researchers are continuing to explore
long-term and emerging effects. Some studies suggest potential concerns such as:



  • Loss of
    lean muscle mass during rapid weight loss
  • Possible effects on
    bone density
  • The need for ongoing therapy to maintain results

A recent
clinical review highlights that although gastrointestinal symptoms dominate,
long-term safety and adherence remain areas of active research.

The Importance of a Doctor-Led Approach

Doctor-led medical weight management programme with ongoing patient monitoring

At
Battersea Hospital, we emphasise that GLP‑1 and GIP therapies are
not standalone solutions. They must be delivered within a
holistic, medically supervised programme that includes:



  • Careful patient selection
  • Gradual dose titration
  • Nutritional and lifestyle support
  • Ongoing monitoring for side effects

This approach ensures that benefits are maximised while risks are minimised.

A Balanced Perspective

GLP‑1 and GIP-based treatments represent a powerful advancement in
weight management. For many patients, the benefits can be life-changing. However, understanding potential side effects—and managing them appropriately—is key to safe and effective outcomes.

With the right
clinical guidance, these therapies can be used as part of a
sustainable, evidence-based strategy for long-term health improvement.